African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Trial StartBundibugyo ebolavirus vaccine candidatePositive

AI Analysis

Summary

Minapharm Group's Bundibugyo ebolavirus vaccine candidate, developed using ProBioGen's MVA-CR19 platform and backed by CEPI funding, is advancing to clinical trials.

Clinical Trial Data

Outcome Details

Vaccine candidate advancing to clinical trials

Importance:6/10

Sentiment:

0.60

vaccineBundibugyo ebolavirusclinical trialAfricainfectious diseaseCEPI funding

Read the original article

Published by PR Newswire Clinical Trials on August 27, 2026 11:27 AM

Read Original